• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    CG Oncology, Inc. - Common stock (NQ: CGON )

    35.53 -0.79 (-2.18%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about CG Oncology, Inc. - Common stock

    This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
    Via Benzinga
    CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
    From CG Oncology Inc.
    Via GlobeNewswire
    CGON Stock Earnings: CG Oncology Beats EPS for Q2 2024
    CGON stock results show that CG Oncology beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
    From CG Oncology Inc.
    Via GlobeNewswire
    A Closer Look at 9 Analyst Recommendations For CG Oncology
    Via Benzinga
    Decoding 10 Analyst Evaluations For CG Oncology
    Via Benzinga
    CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
    - First Patient Dosed in Expanded Access Program and Enrollment Ongoing - 
    From CG Oncology Inc.
    Via GlobeNewswire
    CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
    From CG Oncology Inc.
    Via GlobeNewswire
    Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
    54% complete response (CR) rate at 24-month landmark and meets primary endpoint of the phase 2 study 
    From CG Oncology Inc.
    Via GlobeNewswire
    CGON Stock Earnings: CG Oncology Misses EPS for Q1 2024
    CGON stock results show that CG Oncology missed analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
    From CG Oncology Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
    From CG Oncology Inc.
    Via GlobeNewswire
    Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
    Company to host virtual investor event on Friday, May 3, 2024, at 4:30pm EDT following presentation of results from the Phase 3 BOND-003 trial at the 2024 AUA Annual Meeting 
    From CG Oncology Inc.
    Via GlobeNewswire
    CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
    - Final results of CORE-001 Phase 2 trial of cretostimogene in combination with pembrolizumab for the treatment of BCG-unresponsive NMIBC - 
    From CG Oncology Inc.
    Via GlobeNewswire
    IPO Stocks: Will Reddit Unplug The Bulging U.S. IPO Pipeline?
    A bulging pipeline of IPOs are registered, ready to go, and closely watching Reddit's performance. Here are the concerns. 
    Via Investor's Business Daily
    Topics Initial Public Offering
    Exposures Securities Market
    CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
    - New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting, Practice-changing Clinical Trials in Urology plenary session - 
    From CG Oncology Inc.
    Via GlobeNewswire
    CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
    From CG Oncology Inc.
    Via GlobeNewswire
    Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?
    The market's excited for these stocks, but there's no rush to buy them. 
    Via The Motley Fool
    Topics Initial Public Offering
    Exposures Securities Market
    3 attractive stocks that insiders are buying
    The insiders are buying these attractive stocks. With a bank, a tech, a penny stock, a dividend payer, and a pharmaceutical winner, there is something for all. 
    Via MarketBeat
    CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
    U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From CG Oncology, Inc.
    Via Business Wire
    KKR-Backed BrightSpring Prices Below Expectations, Then Opens Lower
    Health-care services provider BrightSpring, which is backed by private equity firm KKR, priced its initial public offering at $13, below a marketed range of $15 to $18 per share, before opening on... 
    Via Talk Markets
    Topics Initial Public Offering
    Exposures Securities Market
    KLA Reports Q2 Results, Joins Visa, Western Digital And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Friday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.